nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezogabine—NAT2—prostate cancer	0.39	0.712	CbGaD
Ezogabine—CYP2A6—prostate cancer	0.158	0.288	CbGaD
Ezogabine—UGT1A1—Estradiol—prostate cancer	0.0444	0.605	CbGbCtD
Ezogabine—UGT1A1—Etoposide—prostate cancer	0.029	0.395	CbGbCtD
Ezogabine—NAT2—urine—prostate cancer	0.016	0.304	CbGeAlD
Ezogabine—UGT1A1—urine—prostate cancer	0.00591	0.113	CbGeAlD
Ezogabine—KCNQ4—prostate gland—prostate cancer	0.00501	0.0954	CbGeAlD
Ezogabine—KCNQ5—prostate gland—prostate cancer	0.00488	0.0928	CbGeAlD
Ezogabine—NAT2—renal system—prostate cancer	0.00391	0.0744	CbGeAlD
Ezogabine—UGT1A4—renal system—prostate cancer	0.00252	0.0479	CbGeAlD
Ezogabine—KCNQ4—testis—prostate cancer	0.00221	0.042	CbGeAlD
Ezogabine—UGT1A1—prostate gland—prostate cancer	0.00212	0.0404	CbGeAlD
Ezogabine—UGT1A9—renal system—prostate cancer	0.00211	0.0402	CbGeAlD
Ezogabine—CYP2A6—prostate gland—prostate cancer	0.00179	0.0341	CbGeAlD
Ezogabine—KCNQ2—testis—prostate cancer	0.00159	0.0302	CbGeAlD
Ezogabine—KCNQ5—lymph node—prostate cancer	0.00156	0.0296	CbGeAlD
Ezogabine—CYP2A6—seminal vesicle—prostate cancer	0.00151	0.0288	CbGeAlD
Ezogabine—UGT1A1—renal system—prostate cancer	0.00145	0.0275	CbGeAlD
Ezogabine—Oedema peripheral—Docetaxel—prostate cancer	0.000125	0.000793	CcSEcCtD
Ezogabine—Dyspnoea—Estradiol—prostate cancer	0.000124	0.000791	CcSEcCtD
Ezogabine—Somnolence—Estradiol—prostate cancer	0.000124	0.000789	CcSEcCtD
Ezogabine—Weight increased—Prednisone—prostate cancer	0.000124	0.000789	CcSEcCtD
Ezogabine—Urethral disorder—Docetaxel—prostate cancer	0.000124	0.000789	CcSEcCtD
Ezogabine—Osteoarthritis—Epirubicin—prostate cancer	0.000123	0.000785	CcSEcCtD
Ezogabine—Diplopia—Epirubicin—prostate cancer	0.000123	0.000785	CcSEcCtD
Ezogabine—Ill-defined disorder—Etoposide—prostate cancer	0.000123	0.000782	CcSEcCtD
Ezogabine—Dyspepsia—Estradiol—prostate cancer	0.000123	0.000781	CcSEcCtD
Ezogabine—Visual impairment—Docetaxel—prostate cancer	0.000122	0.000776	CcSEcCtD
Ezogabine—Increased appetite—Doxorubicin—prostate cancer	0.000121	0.000773	CcSEcCtD
Ezogabine—Urinary tract disorder—Capecitabine—prostate cancer	0.000121	0.000769	CcSEcCtD
Ezogabine—Oedema peripheral—Capecitabine—prostate cancer	0.000121	0.000768	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Estradiol—prostate cancer	0.00012	0.000766	CcSEcCtD
Ezogabine—Fatigue—Estradiol—prostate cancer	0.00012	0.000765	CcSEcCtD
Ezogabine—Urethral disorder—Capecitabine—prostate cancer	0.00012	0.000764	CcSEcCtD
Ezogabine—Malaise—Etoposide—prostate cancer	0.000119	0.00076	CcSEcCtD
Ezogabine—Constipation—Estradiol—prostate cancer	0.000119	0.000759	CcSEcCtD
Ezogabine—Vertigo—Etoposide—prostate cancer	0.000119	0.000757	CcSEcCtD
Ezogabine—Leukopenia—Etoposide—prostate cancer	0.000119	0.000755	CcSEcCtD
Ezogabine—Eye disorder—Docetaxel—prostate cancer	0.000118	0.000752	CcSEcCtD
Ezogabine—Visual impairment—Capecitabine—prostate cancer	0.000118	0.000751	CcSEcCtD
Ezogabine—Paraesthesia—Mitoxantrone—prostate cancer	0.000117	0.000743	CcSEcCtD
Ezogabine—Loss of consciousness—Etoposide—prostate cancer	0.000116	0.000741	CcSEcCtD
Ezogabine—Dizziness—Goserelin—prostate cancer	0.000116	0.00074	CcSEcCtD
Ezogabine—Dyspnoea—Mitoxantrone—prostate cancer	0.000116	0.000737	CcSEcCtD
Ezogabine—Somnolence—Mitoxantrone—prostate cancer	0.000116	0.000735	CcSEcCtD
Ezogabine—Dizziness—Conjugated Estrogens—prostate cancer	0.000115	0.000733	CcSEcCtD
Ezogabine—Feeling abnormal—Estradiol—prostate cancer	0.000115	0.000731	CcSEcCtD
Ezogabine—Eye disorder—Capecitabine—prostate cancer	0.000114	0.000728	CcSEcCtD
Ezogabine—Dyspepsia—Mitoxantrone—prostate cancer	0.000114	0.000728	CcSEcCtD
Ezogabine—Osteoarthritis—Doxorubicin—prostate cancer	0.000114	0.000726	CcSEcCtD
Ezogabine—Diplopia—Doxorubicin—prostate cancer	0.000114	0.000726	CcSEcCtD
Ezogabine—Liver function test abnormal—Epirubicin—prostate cancer	0.000114	0.000724	CcSEcCtD
Ezogabine—Fatigue—Mitoxantrone—prostate cancer	0.000112	0.000713	CcSEcCtD
Ezogabine—Alopecia—Docetaxel—prostate cancer	0.000112	0.000711	CcSEcCtD
Ezogabine—Discomfort—Etoposide—prostate cancer	0.000111	0.000709	CcSEcCtD
Ezogabine—Constipation—Mitoxantrone—prostate cancer	0.000111	0.000707	CcSEcCtD
Ezogabine—Rash—Goserelin—prostate cancer	0.000111	0.000706	CcSEcCtD
Ezogabine—Dermatitis—Goserelin—prostate cancer	0.000111	0.000705	CcSEcCtD
Ezogabine—Mental disorder—Docetaxel—prostate cancer	0.000111	0.000705	CcSEcCtD
Ezogabine—Malnutrition—Docetaxel—prostate cancer	0.00011	0.000701	CcSEcCtD
Ezogabine—Rash—Conjugated Estrogens—prostate cancer	0.00011	0.000699	CcSEcCtD
Ezogabine—Dermatitis—Conjugated Estrogens—prostate cancer	0.00011	0.000699	CcSEcCtD
Ezogabine—Confusional state—Etoposide—prostate cancer	0.000109	0.000694	CcSEcCtD
Ezogabine—Hallucination—Prednisone—prostate cancer	0.000109	0.000691	CcSEcCtD
Ezogabine—Alopecia—Capecitabine—prostate cancer	0.000108	0.000688	CcSEcCtD
Ezogabine—Infection—Etoposide—prostate cancer	0.000107	0.000683	CcSEcCtD
Ezogabine—Mental disorder—Capecitabine—prostate cancer	0.000107	0.000683	CcSEcCtD
Ezogabine—Feeling abnormal—Mitoxantrone—prostate cancer	0.000107	0.000682	CcSEcCtD
Ezogabine—Malnutrition—Capecitabine—prostate cancer	0.000107	0.000678	CcSEcCtD
Ezogabine—Dysphagia—Epirubicin—prostate cancer	0.000107	0.000678	CcSEcCtD
Ezogabine—Influenza—Epirubicin—prostate cancer	0.000107	0.000678	CcSEcCtD
Ezogabine—Thrombocytopenia—Etoposide—prostate cancer	0.000106	0.000674	CcSEcCtD
Ezogabine—Muscle spasms—Docetaxel—prostate cancer	0.000106	0.000674	CcSEcCtD
Ezogabine—Liver function test abnormal—Doxorubicin—prostate cancer	0.000105	0.00067	CcSEcCtD
Ezogabine—Nausea—Goserelin—prostate cancer	0.000105	0.000665	CcSEcCtD
Ezogabine—Hyperhidrosis—Etoposide—prostate cancer	0.000105	0.000665	CcSEcCtD
Ezogabine—Nausea—Conjugated Estrogens—prostate cancer	0.000104	0.000659	CcSEcCtD
Ezogabine—Muscle spasms—Capecitabine—prostate cancer	0.000103	0.000652	CcSEcCtD
Ezogabine—Eye disorder—Prednisone—prostate cancer	0.000102	0.000649	CcSEcCtD
Ezogabine—Vision blurred—Capecitabine—prostate cancer	0.0001	0.000639	CcSEcCtD
Ezogabine—Asthenia—Estradiol—prostate cancer	0.0001	0.000637	CcSEcCtD
Ezogabine—Tremor—Capecitabine—prostate cancer	9.99e-05	0.000635	CcSEcCtD
Ezogabine—Dysuria—Epirubicin—prostate cancer	9.97e-05	0.000634	CcSEcCtD
Ezogabine—Neutropenia—Epirubicin—prostate cancer	9.97e-05	0.000634	CcSEcCtD
Ezogabine—Ill-defined disorder—Capecitabine—prostate cancer	9.89e-05	0.000629	CcSEcCtD
Ezogabine—Syncope—Docetaxel—prostate cancer	9.88e-05	0.000628	CcSEcCtD
Ezogabine—Influenza—Doxorubicin—prostate cancer	9.86e-05	0.000627	CcSEcCtD
Ezogabine—Dysphagia—Doxorubicin—prostate cancer	9.86e-05	0.000627	CcSEcCtD
Ezogabine—Leukopenia—Docetaxel—prostate cancer	9.86e-05	0.000627	CcSEcCtD
Ezogabine—Paraesthesia—Etoposide—prostate cancer	9.71e-05	0.000618	CcSEcCtD
Ezogabine—Weight increased—Epirubicin—prostate cancer	9.7e-05	0.000617	CcSEcCtD
Ezogabine—Loss of consciousness—Docetaxel—prostate cancer	9.68e-05	0.000616	CcSEcCtD
Ezogabine—Dyspnoea—Etoposide—prostate cancer	9.64e-05	0.000613	CcSEcCtD
Ezogabine—Alopecia—Prednisone—prostate cancer	9.64e-05	0.000613	CcSEcCtD
Ezogabine—Malaise—Capecitabine—prostate cancer	9.61e-05	0.000612	CcSEcCtD
Ezogabine—Somnolence—Etoposide—prostate cancer	9.61e-05	0.000612	CcSEcCtD
Ezogabine—Vertigo—Capecitabine—prostate cancer	9.58e-05	0.000609	CcSEcCtD
Ezogabine—Syncope—Capecitabine—prostate cancer	9.56e-05	0.000608	CcSEcCtD
Ezogabine—Mental disorder—Prednisone—prostate cancer	9.56e-05	0.000608	CcSEcCtD
Ezogabine—Leukopenia—Capecitabine—prostate cancer	9.54e-05	0.000607	CcSEcCtD
Ezogabine—Infestation—Epirubicin—prostate cancer	9.5e-05	0.000605	CcSEcCtD
Ezogabine—Infestation NOS—Epirubicin—prostate cancer	9.5e-05	0.000605	CcSEcCtD
Ezogabine—Malnutrition—Prednisone—prostate cancer	9.5e-05	0.000604	CcSEcCtD
Ezogabine—Loss of consciousness—Capecitabine—prostate cancer	9.37e-05	0.000596	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Etoposide—prostate cancer	9.34e-05	0.000594	CcSEcCtD
Ezogabine—Asthenia—Mitoxantrone—prostate cancer	9.33e-05	0.000593	CcSEcCtD
Ezogabine—Fatigue—Etoposide—prostate cancer	9.32e-05	0.000593	CcSEcCtD
Ezogabine—Constipation—Etoposide—prostate cancer	9.25e-05	0.000588	CcSEcCtD
Ezogabine—Dizziness—Estradiol—prostate cancer	9.23e-05	0.000587	CcSEcCtD
Ezogabine—Dysuria—Doxorubicin—prostate cancer	9.22e-05	0.000587	CcSEcCtD
Ezogabine—Neutropenia—Doxorubicin—prostate cancer	9.22e-05	0.000587	CcSEcCtD
Ezogabine—Dry mouth—Docetaxel—prostate cancer	9.17e-05	0.000583	CcSEcCtD
Ezogabine—Haematuria—Epirubicin—prostate cancer	9.06e-05	0.000576	CcSEcCtD
Ezogabine—Confusional state—Docetaxel—prostate cancer	9.06e-05	0.000576	CcSEcCtD
Ezogabine—Anxiety—Capecitabine—prostate cancer	9.05e-05	0.000575	CcSEcCtD
Ezogabine—Hepatobiliary disease—Epirubicin—prostate cancer	8.99e-05	0.000572	CcSEcCtD
Ezogabine—Weight increased—Doxorubicin—prostate cancer	8.98e-05	0.000571	CcSEcCtD
Ezogabine—Discomfort—Capecitabine—prostate cancer	8.97e-05	0.000571	CcSEcCtD
Ezogabine—Vision blurred—Prednisone—prostate cancer	8.95e-05	0.000569	CcSEcCtD
Ezogabine—Infection—Docetaxel—prostate cancer	8.93e-05	0.000568	CcSEcCtD
Ezogabine—Feeling abnormal—Etoposide—prostate cancer	8.91e-05	0.000567	CcSEcCtD
Ezogabine—Dry mouth—Capecitabine—prostate cancer	8.88e-05	0.000565	CcSEcCtD
Ezogabine—Shock—Docetaxel—prostate cancer	8.84e-05	0.000562	CcSEcCtD
Ezogabine—Nervous system disorder—Docetaxel—prostate cancer	8.81e-05	0.000561	CcSEcCtD
Ezogabine—Ill-defined disorder—Prednisone—prostate cancer	8.81e-05	0.000561	CcSEcCtD
Ezogabine—Thrombocytopenia—Docetaxel—prostate cancer	8.8e-05	0.00056	CcSEcCtD
Ezogabine—Rash—Estradiol—prostate cancer	8.8e-05	0.00056	CcSEcCtD
Ezogabine—Infestation NOS—Doxorubicin—prostate cancer	8.79e-05	0.000559	CcSEcCtD
Ezogabine—Infestation—Doxorubicin—prostate cancer	8.79e-05	0.000559	CcSEcCtD
Ezogabine—Dermatitis—Estradiol—prostate cancer	8.79e-05	0.000559	CcSEcCtD
Ezogabine—Confusional state—Capecitabine—prostate cancer	8.77e-05	0.000558	CcSEcCtD
Ezogabine—Infection—Capecitabine—prostate cancer	8.64e-05	0.00055	CcSEcCtD
Ezogabine—Malaise—Prednisone—prostate cancer	8.56e-05	0.000545	CcSEcCtD
Ezogabine—Shock—Capecitabine—prostate cancer	8.56e-05	0.000545	CcSEcCtD
Ezogabine—Nervous system disorder—Capecitabine—prostate cancer	8.53e-05	0.000543	CcSEcCtD
Ezogabine—Vertigo—Prednisone—prostate cancer	8.53e-05	0.000543	CcSEcCtD
Ezogabine—Thrombocytopenia—Capecitabine—prostate cancer	8.52e-05	0.000542	CcSEcCtD
Ezogabine—Syncope—Prednisone—prostate cancer	8.52e-05	0.000542	CcSEcCtD
Ezogabine—Urinary tract disorder—Epirubicin—prostate cancer	8.43e-05	0.000536	CcSEcCtD
Ezogabine—Hyperhidrosis—Capecitabine—prostate cancer	8.41e-05	0.000535	CcSEcCtD
Ezogabine—Oedema peripheral—Epirubicin—prostate cancer	8.41e-05	0.000535	CcSEcCtD
Ezogabine—Haematuria—Doxorubicin—prostate cancer	8.39e-05	0.000533	CcSEcCtD
Ezogabine—Urethral disorder—Epirubicin—prostate cancer	8.36e-05	0.000532	CcSEcCtD
Ezogabine—Loss of consciousness—Prednisone—prostate cancer	8.35e-05	0.000531	CcSEcCtD
Ezogabine—Hepatobiliary disease—Doxorubicin—prostate cancer	8.32e-05	0.000529	CcSEcCtD
Ezogabine—Nausea—Estradiol—prostate cancer	8.29e-05	0.000527	CcSEcCtD
Ezogabine—Visual impairment—Epirubicin—prostate cancer	8.22e-05	0.000523	CcSEcCtD
Ezogabine—Rash—Mitoxantrone—prostate cancer	8.2e-05	0.000521	CcSEcCtD
Ezogabine—Dermatitis—Mitoxantrone—prostate cancer	8.19e-05	0.000521	CcSEcCtD
Ezogabine—Paraesthesia—Docetaxel—prostate cancer	8.07e-05	0.000513	CcSEcCtD
Ezogabine—Anxiety—Prednisone—prostate cancer	8.06e-05	0.000513	CcSEcCtD
Ezogabine—Dyspnoea—Docetaxel—prostate cancer	8.01e-05	0.00051	CcSEcCtD
Ezogabine—Somnolence—Docetaxel—prostate cancer	7.99e-05	0.000508	CcSEcCtD
Ezogabine—Discomfort—Prednisone—prostate cancer	7.99e-05	0.000508	CcSEcCtD
Ezogabine—Eye disorder—Epirubicin—prostate cancer	7.97e-05	0.000507	CcSEcCtD
Ezogabine—Dyspepsia—Docetaxel—prostate cancer	7.91e-05	0.000503	CcSEcCtD
Ezogabine—Paraesthesia—Capecitabine—prostate cancer	7.81e-05	0.000497	CcSEcCtD
Ezogabine—Urinary tract disorder—Doxorubicin—prostate cancer	7.8e-05	0.000496	CcSEcCtD
Ezogabine—Oedema peripheral—Doxorubicin—prostate cancer	7.78e-05	0.000495	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Docetaxel—prostate cancer	7.76e-05	0.000494	CcSEcCtD
Ezogabine—Asthenia—Etoposide—prostate cancer	7.76e-05	0.000494	CcSEcCtD
Ezogabine—Dyspnoea—Capecitabine—prostate cancer	7.76e-05	0.000493	CcSEcCtD
Ezogabine—Fatigue—Docetaxel—prostate cancer	7.75e-05	0.000493	CcSEcCtD
Ezogabine—Urethral disorder—Doxorubicin—prostate cancer	7.74e-05	0.000492	CcSEcCtD
Ezogabine—Nausea—Mitoxantrone—prostate cancer	7.72e-05	0.000491	CcSEcCtD
Ezogabine—Infection—Prednisone—prostate cancer	7.7e-05	0.00049	CcSEcCtD
Ezogabine—Constipation—Docetaxel—prostate cancer	7.69e-05	0.000489	CcSEcCtD
Ezogabine—Dyspepsia—Capecitabine—prostate cancer	7.66e-05	0.000487	CcSEcCtD
Ezogabine—Shock—Prednisone—prostate cancer	7.63e-05	0.000485	CcSEcCtD
Ezogabine—Visual impairment—Doxorubicin—prostate cancer	7.61e-05	0.000484	CcSEcCtD
Ezogabine—Nervous system disorder—Prednisone—prostate cancer	7.6e-05	0.000484	CcSEcCtD
Ezogabine—Alopecia—Epirubicin—prostate cancer	7.54e-05	0.00048	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Capecitabine—prostate cancer	7.51e-05	0.000478	CcSEcCtD
Ezogabine—Fatigue—Capecitabine—prostate cancer	7.5e-05	0.000477	CcSEcCtD
Ezogabine—Hyperhidrosis—Prednisone—prostate cancer	7.49e-05	0.000477	CcSEcCtD
Ezogabine—Mental disorder—Epirubicin—prostate cancer	7.48e-05	0.000476	CcSEcCtD
Ezogabine—Constipation—Capecitabine—prostate cancer	7.44e-05	0.000473	CcSEcCtD
Ezogabine—Malnutrition—Epirubicin—prostate cancer	7.43e-05	0.000473	CcSEcCtD
Ezogabine—Feeling abnormal—Docetaxel—prostate cancer	7.41e-05	0.000471	CcSEcCtD
Ezogabine—Eye disorder—Doxorubicin—prostate cancer	7.38e-05	0.000469	CcSEcCtD
Ezogabine—Feeling abnormal—Capecitabine—prostate cancer	7.17e-05	0.000456	CcSEcCtD
Ezogabine—Dizziness—Etoposide—prostate cancer	7.15e-05	0.000455	CcSEcCtD
Ezogabine—Muscle spasms—Epirubicin—prostate cancer	7.14e-05	0.000454	CcSEcCtD
Ezogabine—Vision blurred—Epirubicin—prostate cancer	7e-05	0.000445	CcSEcCtD
Ezogabine—Alopecia—Doxorubicin—prostate cancer	6.98e-05	0.000444	CcSEcCtD
Ezogabine—Paraesthesia—Prednisone—prostate cancer	6.96e-05	0.000443	CcSEcCtD
Ezogabine—Mental disorder—Doxorubicin—prostate cancer	6.92e-05	0.00044	CcSEcCtD
Ezogabine—Ill-defined disorder—Epirubicin—prostate cancer	6.89e-05	0.000438	CcSEcCtD
Ezogabine—Malnutrition—Doxorubicin—prostate cancer	6.87e-05	0.000437	CcSEcCtD
Ezogabine—Dyspepsia—Prednisone—prostate cancer	6.82e-05	0.000434	CcSEcCtD
Ezogabine—Rash—Etoposide—prostate cancer	6.82e-05	0.000434	CcSEcCtD
Ezogabine—Dermatitis—Etoposide—prostate cancer	6.81e-05	0.000433	CcSEcCtD
Ezogabine—Malaise—Epirubicin—prostate cancer	6.7e-05	0.000426	CcSEcCtD
Ezogabine—Fatigue—Prednisone—prostate cancer	6.68e-05	0.000425	CcSEcCtD
Ezogabine—Vertigo—Epirubicin—prostate cancer	6.67e-05	0.000425	CcSEcCtD
Ezogabine—Syncope—Epirubicin—prostate cancer	6.66e-05	0.000424	CcSEcCtD
Ezogabine—Leukopenia—Epirubicin—prostate cancer	6.65e-05	0.000423	CcSEcCtD
Ezogabine—Constipation—Prednisone—prostate cancer	6.63e-05	0.000422	CcSEcCtD
Ezogabine—Muscle spasms—Doxorubicin—prostate cancer	6.61e-05	0.00042	CcSEcCtD
Ezogabine—Loss of consciousness—Epirubicin—prostate cancer	6.53e-05	0.000415	CcSEcCtD
Ezogabine—Vision blurred—Doxorubicin—prostate cancer	6.48e-05	0.000412	CcSEcCtD
Ezogabine—Asthenia—Docetaxel—prostate cancer	6.45e-05	0.00041	CcSEcCtD
Ezogabine—Nausea—Etoposide—prostate cancer	6.42e-05	0.000409	CcSEcCtD
Ezogabine—Feeling abnormal—Prednisone—prostate cancer	6.39e-05	0.000406	CcSEcCtD
Ezogabine—Ill-defined disorder—Doxorubicin—prostate cancer	6.38e-05	0.000406	CcSEcCtD
Ezogabine—Anxiety—Epirubicin—prostate cancer	6.3e-05	0.000401	CcSEcCtD
Ezogabine—Discomfort—Epirubicin—prostate cancer	6.25e-05	0.000397	CcSEcCtD
Ezogabine—Asthenia—Capecitabine—prostate cancer	6.24e-05	0.000397	CcSEcCtD
Ezogabine—Malaise—Doxorubicin—prostate cancer	6.2e-05	0.000394	CcSEcCtD
Ezogabine—Dry mouth—Epirubicin—prostate cancer	6.18e-05	0.000393	CcSEcCtD
Ezogabine—Vertigo—Doxorubicin—prostate cancer	6.17e-05	0.000393	CcSEcCtD
Ezogabine—Syncope—Doxorubicin—prostate cancer	6.16e-05	0.000392	CcSEcCtD
Ezogabine—Leukopenia—Doxorubicin—prostate cancer	6.15e-05	0.000391	CcSEcCtD
Ezogabine—Confusional state—Epirubicin—prostate cancer	6.11e-05	0.000389	CcSEcCtD
Ezogabine—Loss of consciousness—Doxorubicin—prostate cancer	6.04e-05	0.000384	CcSEcCtD
Ezogabine—Infection—Epirubicin—prostate cancer	6.02e-05	0.000383	CcSEcCtD
Ezogabine—Shock—Epirubicin—prostate cancer	5.96e-05	0.000379	CcSEcCtD
Ezogabine—Nervous system disorder—Epirubicin—prostate cancer	5.94e-05	0.000378	CcSEcCtD
Ezogabine—Dizziness—Docetaxel—prostate cancer	5.94e-05	0.000378	CcSEcCtD
Ezogabine—Thrombocytopenia—Epirubicin—prostate cancer	5.94e-05	0.000378	CcSEcCtD
Ezogabine—Hyperhidrosis—Epirubicin—prostate cancer	5.86e-05	0.000373	CcSEcCtD
Ezogabine—Anxiety—Doxorubicin—prostate cancer	5.83e-05	0.000371	CcSEcCtD
Ezogabine—Discomfort—Doxorubicin—prostate cancer	5.78e-05	0.000368	CcSEcCtD
Ezogabine—Dizziness—Capecitabine—prostate cancer	5.75e-05	0.000366	CcSEcCtD
Ezogabine—Dry mouth—Doxorubicin—prostate cancer	5.72e-05	0.000364	CcSEcCtD
Ezogabine—Rash—Docetaxel—prostate cancer	5.67e-05	0.00036	CcSEcCtD
Ezogabine—Dermatitis—Docetaxel—prostate cancer	5.66e-05	0.00036	CcSEcCtD
Ezogabine—Confusional state—Doxorubicin—prostate cancer	5.66e-05	0.00036	CcSEcCtD
Ezogabine—Infection—Doxorubicin—prostate cancer	5.57e-05	0.000354	CcSEcCtD
Ezogabine—Asthenia—Prednisone—prostate cancer	5.56e-05	0.000354	CcSEcCtD
Ezogabine—Shock—Doxorubicin—prostate cancer	5.52e-05	0.000351	CcSEcCtD
Ezogabine—Nervous system disorder—Doxorubicin—prostate cancer	5.5e-05	0.00035	CcSEcCtD
Ezogabine—Thrombocytopenia—Doxorubicin—prostate cancer	5.49e-05	0.000349	CcSEcCtD
Ezogabine—Rash—Capecitabine—prostate cancer	5.49e-05	0.000349	CcSEcCtD
Ezogabine—Dermatitis—Capecitabine—prostate cancer	5.48e-05	0.000349	CcSEcCtD
Ezogabine—Paraesthesia—Epirubicin—prostate cancer	5.44e-05	0.000346	CcSEcCtD
Ezogabine—Hyperhidrosis—Doxorubicin—prostate cancer	5.42e-05	0.000345	CcSEcCtD
Ezogabine—Dyspnoea—Epirubicin—prostate cancer	5.4e-05	0.000344	CcSEcCtD
Ezogabine—Somnolence—Epirubicin—prostate cancer	5.39e-05	0.000343	CcSEcCtD
Ezogabine—Nausea—Docetaxel—prostate cancer	5.34e-05	0.00034	CcSEcCtD
Ezogabine—Dyspepsia—Epirubicin—prostate cancer	5.34e-05	0.000339	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Epirubicin—prostate cancer	5.23e-05	0.000333	CcSEcCtD
Ezogabine—Fatigue—Epirubicin—prostate cancer	5.23e-05	0.000332	CcSEcCtD
Ezogabine—Constipation—Epirubicin—prostate cancer	5.18e-05	0.00033	CcSEcCtD
Ezogabine—Nausea—Capecitabine—prostate cancer	5.17e-05	0.000329	CcSEcCtD
Ezogabine—Dizziness—Prednisone—prostate cancer	5.13e-05	0.000326	CcSEcCtD
Ezogabine—Paraesthesia—Doxorubicin—prostate cancer	5.04e-05	0.00032	CcSEcCtD
Ezogabine—Dyspnoea—Doxorubicin—prostate cancer	5e-05	0.000318	CcSEcCtD
Ezogabine—Feeling abnormal—Epirubicin—prostate cancer	5e-05	0.000318	CcSEcCtD
Ezogabine—Somnolence—Doxorubicin—prostate cancer	4.99e-05	0.000317	CcSEcCtD
Ezogabine—Dyspepsia—Doxorubicin—prostate cancer	4.94e-05	0.000314	CcSEcCtD
Ezogabine—Rash—Prednisone—prostate cancer	4.89e-05	0.000311	CcSEcCtD
Ezogabine—Dermatitis—Prednisone—prostate cancer	4.88e-05	0.000311	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Doxorubicin—prostate cancer	4.84e-05	0.000308	CcSEcCtD
Ezogabine—Fatigue—Doxorubicin—prostate cancer	4.84e-05	0.000308	CcSEcCtD
Ezogabine—Constipation—Doxorubicin—prostate cancer	4.8e-05	0.000305	CcSEcCtD
Ezogabine—Feeling abnormal—Doxorubicin—prostate cancer	4.62e-05	0.000294	CcSEcCtD
Ezogabine—Nausea—Prednisone—prostate cancer	4.6e-05	0.000293	CcSEcCtD
Ezogabine—Asthenia—Epirubicin—prostate cancer	4.35e-05	0.000277	CcSEcCtD
Ezogabine—Asthenia—Doxorubicin—prostate cancer	4.02e-05	0.000256	CcSEcCtD
Ezogabine—Dizziness—Epirubicin—prostate cancer	4.01e-05	0.000255	CcSEcCtD
Ezogabine—Rash—Epirubicin—prostate cancer	3.82e-05	0.000243	CcSEcCtD
Ezogabine—Dermatitis—Epirubicin—prostate cancer	3.82e-05	0.000243	CcSEcCtD
Ezogabine—Dizziness—Doxorubicin—prostate cancer	3.71e-05	0.000236	CcSEcCtD
Ezogabine—Nausea—Epirubicin—prostate cancer	3.6e-05	0.000229	CcSEcCtD
Ezogabine—Rash—Doxorubicin—prostate cancer	3.54e-05	0.000225	CcSEcCtD
Ezogabine—Dermatitis—Doxorubicin—prostate cancer	3.53e-05	0.000225	CcSEcCtD
Ezogabine—Nausea—Doxorubicin—prostate cancer	3.33e-05	0.000212	CcSEcCtD
Ezogabine—UGT1A9—Metabolism—HSD3B2—prostate cancer	9.55e-06	5.65e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GSTO1—prostate cancer	9.55e-06	5.65e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NAT2—prostate cancer	9.55e-06	5.65e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NAT2—prostate cancer	9.55e-06	5.65e-05	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—INS—prostate cancer	9.53e-06	5.64e-05	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—CREBBP—prostate cancer	9.33e-06	5.52e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—RXRA—prostate cancer	9.32e-06	5.52e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—UMPS—prostate cancer	9.31e-06	5.51e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ARG2—prostate cancer	9.31e-06	5.51e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PHGDH—prostate cancer	9.31e-06	5.51e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—SLC5A5—prostate cancer	9.22e-06	5.46e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	9.18e-06	5.44e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PLCB2—prostate cancer	9.16e-06	5.42e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PLCB2—prostate cancer	9.16e-06	5.42e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CYP2C18—prostate cancer	9.16e-06	5.42e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—LRP2—prostate cancer	9.16e-06	5.42e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—LRP2—prostate cancer	9.16e-06	5.42e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CYP2C18—prostate cancer	9.16e-06	5.42e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—LDHB—prostate cancer	9.13e-06	5.41e-05	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—AKT1—prostate cancer	9.08e-06	5.37e-05	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—AKT1—prostate cancer	9.08e-06	5.37e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CYP2E1—prostate cancer	9.01e-06	5.33e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—P4HB—prostate cancer	8.98e-06	5.32e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—COMT—prostate cancer	8.98e-06	5.32e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—P4HB—prostate cancer	8.98e-06	5.32e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CYP3A5—prostate cancer	8.97e-06	5.31e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—GSTP1—prostate cancer	8.94e-06	5.29e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—NQO1—prostate cancer	8.91e-06	5.27e-05	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PIK3CD—prostate cancer	8.85e-06	5.24e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—ITPR1—prostate cancer	8.79e-06	5.21e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—TH—prostate cancer	8.78e-06	5.2e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—SLC22A1—prostate cancer	8.74e-06	5.17e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—SLC22A1—prostate cancer	8.74e-06	5.17e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CYP3A4—prostate cancer	8.69e-06	5.14e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PDHA1—prostate cancer	8.66e-06	5.13e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GSTA3—prostate cancer	8.66e-06	5.13e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—UCP3—prostate cancer	8.66e-06	5.13e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—TCN2—prostate cancer	8.66e-06	5.13e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	8.63e-06	5.11e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CYP1B1—prostate cancer	8.54e-06	5.05e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—SULT2A1—prostate cancer	8.51e-06	5.04e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—SULT2A1—prostate cancer	8.51e-06	5.04e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—MED12—prostate cancer	8.37e-06	4.96e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—MED12—prostate cancer	8.37e-06	4.96e-05	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—NOS3—prostate cancer	8.36e-06	4.95e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—TYMS—prostate cancer	8.31e-06	4.92e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GNG5—prostate cancer	8.31e-06	4.92e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GNG5—prostate cancer	8.31e-06	4.92e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GGT1—prostate cancer	8.27e-06	4.9e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—SLC22A3—prostate cancer	8.26e-06	4.89e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—HSD3B1—prostate cancer	8.26e-06	4.89e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—GSTM1—prostate cancer	8.21e-06	4.86e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—NCOA1—prostate cancer	8.15e-06	4.82e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—LPL—prostate cancer	8.06e-06	4.77e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CYP19A1—prostate cancer	8.03e-06	4.75e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NCOA3—prostate cancer	8e-06	4.74e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NCOA3—prostate cancer	8e-06	4.74e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—TBXAS1—prostate cancer	7.92e-06	4.69e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GSTA4—prostate cancer	7.92e-06	4.69e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	7.87e-06	4.66e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CYP1A1—prostate cancer	7.79e-06	4.61e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—RXRA—prostate cancer	7.75e-06	4.59e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—ERCC2—prostate cancer	7.72e-06	4.57e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GSTA2—prostate cancer	7.72e-06	4.57e-05	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PIK3CB—prostate cancer	7.71e-06	4.57e-05	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PTGS2—prostate cancer	7.64e-06	4.52e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—HPGDS—prostate cancer	7.64e-06	4.52e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—HPGDS—prostate cancer	7.64e-06	4.52e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—SULT1A1—prostate cancer	7.62e-06	4.51e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ABCG5—prostate cancer	7.62e-06	4.51e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CYP2C19—prostate cancer	7.59e-06	4.49e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CYP2C19—prostate cancer	7.59e-06	4.49e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—COMT—prostate cancer	7.46e-06	4.42e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GSTA1—prostate cancer	7.45e-06	4.41e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GSTP1—prostate cancer	7.43e-06	4.4e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ACHE—prostate cancer	7.41e-06	4.38e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ACHE—prostate cancer	7.41e-06	4.38e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GSTT1—prostate cancer	7.41e-06	4.38e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GSTT1—prostate cancer	7.41e-06	4.38e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—HSD3B2—prostate cancer	7.36e-06	4.36e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GSTO1—prostate cancer	7.36e-06	4.36e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NAT2—prostate cancer	7.36e-06	4.36e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CYP2A6—prostate cancer	7.32e-06	4.33e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CYP2A6—prostate cancer	7.32e-06	4.33e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—ITPR1—prostate cancer	7.31e-06	4.33e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	7.29e-06	4.32e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—MTHFR—prostate cancer	7.26e-06	4.3e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PPARA—prostate cancer	7.12e-06	4.21e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—AKR1C3—prostate cancer	7.12e-06	4.21e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—AKR1C3—prostate cancer	7.12e-06	4.21e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PRKACB—prostate cancer	7.08e-06	4.19e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PRKACB—prostate cancer	7.08e-06	4.19e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PLCB2—prostate cancer	7.06e-06	4.18e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—LRP2—prostate cancer	7.06e-06	4.18e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CYP2C18—prostate cancer	7.06e-06	4.18e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CYP17A1—prostate cancer	7.01e-06	4.15e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CYP17A1—prostate cancer	7.01e-06	4.15e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—P4HB—prostate cancer	6.92e-06	4.1e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	6.91e-06	4.09e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—TYMS—prostate cancer	6.91e-06	4.09e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GSTM1—prostate cancer	6.83e-06	4.04e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—SLC22A1—prostate cancer	6.73e-06	3.99e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—LPL—prostate cancer	6.7e-06	3.97e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CAV1—prostate cancer	6.7e-06	3.96e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NCOA2—prostate cancer	6.68e-06	3.95e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NCOA2—prostate cancer	6.68e-06	3.95e-05	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PTEN—prostate cancer	6.66e-06	3.94e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—SULT2A1—prostate cancer	6.56e-06	3.88e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CYP1A1—prostate cancer	6.47e-06	3.83e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—MED12—prostate cancer	6.46e-06	3.82e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—ERCC2—prostate cancer	6.42e-06	3.8e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GNG5—prostate cancer	6.41e-06	3.79e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—SLC5A5—prostate cancer	6.37e-06	3.77e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—SLC5A5—prostate cancer	6.37e-06	3.77e-05	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—EP300—prostate cancer	6.36e-06	3.76e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CYP2E1—prostate cancer	6.22e-06	3.68e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CYP2E1—prostate cancer	6.22e-06	3.68e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NCOA3—prostate cancer	6.17e-06	3.65e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NQO1—prostate cancer	6.15e-06	3.64e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NQO1—prostate cancer	6.15e-06	3.64e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PIK3CG—prostate cancer	6.1e-06	3.61e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—TH—prostate cancer	6.07e-06	3.59e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—TH—prostate cancer	6.07e-06	3.59e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—MTHFR—prostate cancer	6.03e-06	3.57e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	6.03e-06	3.57e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CYP3A4—prostate cancer	6e-06	3.55e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CYP3A4—prostate cancer	6e-06	3.55e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	5.97e-06	3.53e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PPARA—prostate cancer	5.92e-06	3.5e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CYP1B1—prostate cancer	5.9e-06	3.49e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CYP1B1—prostate cancer	5.9e-06	3.49e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—HPGDS—prostate cancer	5.89e-06	3.48e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CYP2C19—prostate cancer	5.85e-06	3.46e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—INS—prostate cancer	5.77e-06	3.42e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GGT1—prostate cancer	5.71e-06	3.38e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GGT1—prostate cancer	5.71e-06	3.38e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ACHE—prostate cancer	5.71e-06	3.38e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GSTT1—prostate cancer	5.71e-06	3.38e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CREBBP—prostate cancer	5.65e-06	3.35e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NCOA1—prostate cancer	5.63e-06	3.33e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NCOA1—prostate cancer	5.63e-06	3.33e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CAV1—prostate cancer	5.57e-06	3.29e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CYP19A1—prostate cancer	5.55e-06	3.28e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CYP19A1—prostate cancer	5.55e-06	3.28e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—AKR1C3—prostate cancer	5.49e-06	3.25e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PRKACB—prostate cancer	5.46e-06	3.23e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CYP17A1—prostate cancer	5.4e-06	3.2e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PIK3CD—prostate cancer	5.36e-06	3.17e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—RXRA—prostate cancer	5.35e-06	3.17e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—RXRA—prostate cancer	5.35e-06	3.17e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	5.21e-06	3.08e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—COMT—prostate cancer	5.16e-06	3.05e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—COMT—prostate cancer	5.16e-06	3.05e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NCOA2—prostate cancer	5.15e-06	3.05e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GSTP1—prostate cancer	5.13e-06	3.04e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GSTP1—prostate cancer	5.13e-06	3.04e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PIK3CG—prostate cancer	5.07e-06	3e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—NOS3—prostate cancer	5.06e-06	3e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ITPR1—prostate cancer	5.05e-06	2.99e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ITPR1—prostate cancer	5.05e-06	2.99e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	4.97e-06	2.94e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—SLC5A5—prostate cancer	4.91e-06	2.91e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—INS—prostate cancer	4.8e-06	2.84e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CYP2E1—prostate cancer	4.8e-06	2.84e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—TYMS—prostate cancer	4.77e-06	2.82e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—TYMS—prostate cancer	4.77e-06	2.82e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NQO1—prostate cancer	4.74e-06	2.81e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GSTM1—prostate cancer	4.72e-06	2.79e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GSTM1—prostate cancer	4.72e-06	2.79e-05	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PIK3CA—prostate cancer	4.7e-06	2.78e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CREBBP—prostate cancer	4.7e-06	2.78e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—TH—prostate cancer	4.68e-06	2.77e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PIK3CB—prostate cancer	4.67e-06	2.77e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PTGS2—prostate cancer	4.63e-06	2.74e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—LPL—prostate cancer	4.63e-06	2.74e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—LPL—prostate cancer	4.63e-06	2.74e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CYP3A4—prostate cancer	4.63e-06	2.74e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CYP1B1—prostate cancer	4.55e-06	2.69e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CYP1A1—prostate cancer	4.47e-06	2.65e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CYP1A1—prostate cancer	4.47e-06	2.65e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PIK3CD—prostate cancer	4.46e-06	2.64e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ERCC2—prostate cancer	4.44e-06	2.63e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ERCC2—prostate cancer	4.44e-06	2.63e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GGT1—prostate cancer	4.41e-06	2.61e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NCOA1—prostate cancer	4.34e-06	2.57e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CYP19A1—prostate cancer	4.28e-06	2.53e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—NOS3—prostate cancer	4.21e-06	2.49e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—MTHFR—prostate cancer	4.17e-06	2.47e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—MTHFR—prostate cancer	4.17e-06	2.47e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—RXRA—prostate cancer	4.13e-06	2.44e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PPARA—prostate cancer	4.09e-06	2.42e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PPARA—prostate cancer	4.09e-06	2.42e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PTEN—prostate cancer	4.04e-06	2.39e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—COMT—prostate cancer	3.98e-06	2.35e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GSTP1—prostate cancer	3.96e-06	2.34e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ITPR1—prostate cancer	3.89e-06	2.3e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PIK3CB—prostate cancer	3.88e-06	2.3e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—EP300—prostate cancer	3.85e-06	2.28e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PTGS2—prostate cancer	3.85e-06	2.28e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CAV1—prostate cancer	3.85e-06	2.28e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CAV1—prostate cancer	3.85e-06	2.28e-05	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—AKT1—prostate cancer	3.84e-06	2.27e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—TYMS—prostate cancer	3.68e-06	2.18e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.67e-06	2.17e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GSTM1—prostate cancer	3.64e-06	2.15e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—LPL—prostate cancer	3.57e-06	2.11e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PIK3CG—prostate cancer	3.5e-06	2.07e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PIK3CG—prostate cancer	3.5e-06	2.07e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CYP1A1—prostate cancer	3.45e-06	2.04e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ERCC2—prostate cancer	3.42e-06	2.02e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PTEN—prostate cancer	3.36e-06	1.99e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—INS—prostate cancer	3.32e-06	1.96e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—INS—prostate cancer	3.32e-06	1.96e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CREBBP—prostate cancer	3.25e-06	1.92e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CREBBP—prostate cancer	3.25e-06	1.92e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—MTHFR—prostate cancer	3.21e-06	1.9e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—EP300—prostate cancer	3.2e-06	1.89e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PPARA—prostate cancer	3.15e-06	1.87e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PIK3CD—prostate cancer	3.08e-06	1.82e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PIK3CD—prostate cancer	3.08e-06	1.82e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CAV1—prostate cancer	2.96e-06	1.75e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NOS3—prostate cancer	2.91e-06	1.72e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NOS3—prostate cancer	2.91e-06	1.72e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PIK3CA—prostate cancer	2.85e-06	1.69e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PIK3CG—prostate cancer	2.7e-06	1.6e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PIK3CB—prostate cancer	2.68e-06	1.59e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PIK3CB—prostate cancer	2.68e-06	1.59e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PTGS2—prostate cancer	2.66e-06	1.57e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PTGS2—prostate cancer	2.66e-06	1.57e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—INS—prostate cancer	2.56e-06	1.51e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CREBBP—prostate cancer	2.5e-06	1.48e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PIK3CD—prostate cancer	2.37e-06	1.4e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PIK3CA—prostate cancer	2.37e-06	1.4e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—AKT1—prostate cancer	2.33e-06	1.38e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PTEN—prostate cancer	2.32e-06	1.37e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PTEN—prostate cancer	2.32e-06	1.37e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NOS3—prostate cancer	2.24e-06	1.33e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—EP300—prostate cancer	2.21e-06	1.31e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—EP300—prostate cancer	2.21e-06	1.31e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PIK3CB—prostate cancer	2.07e-06	1.22e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PTGS2—prostate cancer	2.05e-06	1.21e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—AKT1—prostate cancer	1.93e-06	1.14e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PTEN—prostate cancer	1.79e-06	1.06e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—EP300—prostate cancer	1.7e-06	1.01e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PIK3CA—prostate cancer	1.64e-06	9.68e-06	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PIK3CA—prostate cancer	1.64e-06	9.68e-06	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—AKT1—prostate cancer	1.34e-06	7.91e-06	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—AKT1—prostate cancer	1.34e-06	7.91e-06	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PIK3CA—prostate cancer	1.26e-06	7.47e-06	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—AKT1—prostate cancer	1.03e-06	6.1e-06	CbGpPWpGaD
